Table 3. . β-adrenergic outcomes.
| Studies | Outcome assessed | Results | Ref. | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Survival | RFS | Mortality | Incidence | Survival | RFS | Mortality | Incidence | ||
| β-blockers without considering cancer treatments | |||||||||
| Weberpals et al., 2017 | x | - | [53] | ||||||
| Shah et al., 2011 | x | - | [47] | ||||||
| Holmes et al., 2013 | x | - | [39] | ||||||
| Yang et al., 2017 | x | - | [54] | ||||||
| Cui et al., 2019 | x | x | - | - | [56] | ||||
| Udumyan et al., 2020 | x | - | [49] | ||||||
| Lin et al., 2015 | x | ✓ | [41] | ||||||
| Numbere et al., 2015 | x | - | [44] | ||||||
| β-blockers associated with cancer treatments | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Chang et al., 2020 | x | ✓ | [36] | ||||||
| Chaudhary et al., 2019 | x | x | ✓ | ✓ | [37] | ||||
| Wang et al., 2013 | x | x | ✓ | ✓ | [51] | ||||
| Aydiner et al., 2013 | x | ✓ | [34] | ||||||
| Oh et al., 2020 | x | x | ✓ | ✓ | [45] | ||||
| Wang et al., 2015 | x | x | ✓ | ✓ | [52] |
| β-blockers during the perioperative period | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cata et al., 2014 | x | x | - | - | [35] | ||||
| Sakamoto et al., 2019 | x | x | ✓ | ✓ | [46] | ||||
| Musselman et al., 2018 | x | x | - | - | [43] |
RFS: Recurrence-free survival; x: Evaluation performed; ✓: Significant difference; -: No significance.